Glutaminolysis is Essential for Myofibroblast Persistence and In Vivo Targeting Reverses Fibrosis and Cardiac Dysfunction in Heart Failure

被引：20

作者：

Gibb, Andrew A. ^{[1
]}

Murray, Emma K. ^{[1
]}

Huynh, Anh T. ^{[1
]}

Gaspar, Ryan B. ^{[1
]}

Ploesch, Tori L. ^{[1
]}

Bedi, Ken ^{[4
,5
]}

Lombardi, Alyssa A. ^{[1
]}

Lorkiewicz, Pawel K. ^{[2
]}

Roy, Rajika ^{[1
]}

Arany, Zolt ^{[4
,5
]}

Kelly, Daniel P. ^{[4
,5
]}

Margulies, Kenneth B. ^{[4
,5
]}

Hill, Bradford G. ^{[3
]}

Elrod, John W. ^{[1
]}

机构：

[1] Temple Univ, Lewis Katz Sch Med, Dept Cardiovasc Sci, Ctr Translat Med, Philadelphia, PA 19122 USA

[2] Univ Louisville, Dept Chem, Louisville, KY 40292 USA

[3] Univ Louisville, Div Environm Med, Louisville, KY 40292 USA

[4] Univ Penn, Dept Med, Cardiovasc Inst, Perelman Sch Med, Philadelphia, PA 19104 USA

[5] Univ Penn, Dept Med, Cardiovasc Med Div, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CIRCULATION | 2022年 / 145卷 / 21期

基金：

美国国家卫生研究院;

关键词：

fibrosis; glutamine; heart failure; metabolism; myofibroblasts;

D O I：

10.1161/CIRCULATIONAHA.121.057879

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1625 / 1628

页数：4

共 50 条

[1] Targeting the Cardiac Myofibroblast Secretome to Treat Myocardial Fibrosis in Heart Failure
Weber, Karl T.
Diez, Javier
CIRCULATION-HEART FAILURE, 2016, 9 (08)
[2] Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis
Teng, Guoqi
Svystonyuk, Daniyil
Mewhort, Holly E. M.
Turnbull, Jeannine D.
Belke, Darrell D.
Duff, Henry J.
Fedak, Paul W. M.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2015, 308 (12): : H1564 - H1574
[3] HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation
Nural-Guvener, Hikmet F.
Zakharova, Luidmila
Nimlos, James
Popovic, Snjezana
Mastroeni, Diego
Gaballa, Mohamed A.
FIBROGENESIS & TISSUE REPAIR, 2014, 7
[4] Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, Mark
Corden, Ben
Cook, Stuart A.
EMBO MOLECULAR MEDICINE, 2020, 12 (10)
[5] Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure
Matsumoto, T
Wada, A
Tsutamoto, T
Ohnishi, M
Isono, T
Kinoshita, M
CIRCULATION, 2003, 107 (20) : 2555 - 2558
[6] Cardiac Reprogramming Reduces Fibrosis and Improves Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction
Yamada, Yu
Sadahiro, Taketaro
Nakano, Koji
Honda, Seiichiro
Abe, Yuto
Fujita, Ryo
Ieda, Masaki
CIRCULATION, 2023, 148
[7] In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction
Shah, AS
White, DC
Emani, S
Kypson, AP
Lilly, RE
Wilson, K
Glower, DD
Lefkowitz, RJ
Koch, WJ
CIRCULATION, 2001, 103 (09) : 1311 - 1316
[8] Markers of fibrosis in ischemic chronic heart failure and renal dysfunction
Syvolap, V. D.
Lashkul, D. A.
ZAPOROZHYE MEDICAL JOURNAL, 2015, (03) : 24 - 28
[9] Autoantibodies in Heart Failure and Cardiac Dysfunction
Kaya, Ziya
Leib, Christoph
Katus, Hugo A.
CIRCULATION RESEARCH, 2012, 110 (01) : 145 - 158
[10] Pharmacological inhibition of ε-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure
Inagaki, Koichi
Koyanagi, Tomoyoshi
Berry, Natalia C.
Sun, Lihan
Mochly-Rosen, Daria
HYPERTENSION, 2008, 51 (06) : 1565 - 1569

← 1 2 3 4 5 →